Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

muscle volume z-score and muscle fat infiltration in people with type 2 diabetes (T2D) A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Novo Nordisk's semaglutide is the active compound in Ozempic and Wegovy, while Lilly's tirzepatide is the active drug in Mounjaro and Zepbound.

1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH. ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic ...